You are here

AusPAR: Cabotegravir sodium and cabotegravir/rilpivirine

Australian Public Assessment Report

19 May 2021
AusPAR Details
AusPAR
Active Ingredient
Cabotegravir sodium and cabotegravir/rilpivirine
Product Name
Vocabria and Cabenuva
Sponsor
ViiV Healthcare Pty Ltd
Submission Number
PM-2019-04281-1-2 and PM-2019-04280-1-2
Submission Type
New chemical entity and New fixed dose combination
Decision
Both approved
AusPAR Date
3 May 2021
Publication Date

19 May 2021